Next Article in Journal
Clinicopathologic Features of Early Gastric Cancer after Helicobacter pylori Eradication in Japanese Patients: Comparative Study between Early (<10 Years) and Late (>10 Years) Onset
Previous Article in Journal
Therapeutic Opportunities for Biomarkers in Metastatic Spine Tumors
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 16
Issue 18
10.3390/cancers16183153
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Trends in Cancer Incidence and Mortality in US Adolescents and Young Adults, 2016–2021

by
Li Zhang
1,
Joshua E. Muscat
1,*,
Vernon M. Chinchilli
2 and
Chandrika G. Behura
3,*
1
Center for Research on Tobacco and Health, Department of Public Health Sciences, Penn State College of Medicine, Hershey, PA 17033, USA
2
Department of Public Health Sciences, Penn State College of Medicine, Hershey, PA 17033, USA
3
Department of Pediatrics, Penn State Children’s Hospital, Penn State University College of Medicine, Hershey, PA 17033, USA
*
Authors to whom correspondence should be addressed.
Cancers 2024, 16(18), 3153; https://doi.org/10.3390/cancers16183153
Submission received: 18 August 2024 / Revised: 9 September 2024 / Accepted: 11 September 2024 / Published: 14 September 2024
(This article belongs to the Section Cancer Epidemiology and Prevention)
Review Reports Versions Notes

Abstract

:

Simple Summary

The incidence and mortality rates of cancer in the Surveillance, Epidemiology, and End Results (SEER) Program for adolescent and young adult (AYA) patients show distinct patterns among early-onset cancers. For some cancers, AYA cancer rates varied by age group, sex, race, ethnicity and geography. Monitoring the rates and time trends of AYA cancer emphasizes the distinct health concern for this age group.

Abstract

(1) Background: The incidence rate of early onset-cancer (<50) has increased since 1995. Among younger people, cancers in AYAs (aged 15–39 y) are often biologically distinct tumors from those treated in the pediatric and older adult population. The current study describes trends in the United States for the most recent years including the first year of the COVID-19 epidemic. We aimed to describe the recent incidence and mortality trends of cancers in AYAs (aged 15–39 y). (2) Methods: We used data from the Surveillance, Epidemiology, and End Results (SEER 22) from 1 January 2016 to 31 December 2021. Age-adjusted incidence and mortality rates were assessed by SEER*Stat 8.4.3 for major cancer types by sex, race/ethnicity, age, and metropolitan/nonmetropolitan status. Time trends of age-adjusted incidence and mortality rates were examined by sex and metropolitan/nonmetropolitan status. (3) Results: Age-adjusted overall cancer incidence and mortality rates were stable during this study period. The age-adjusted incidence rates declined significantly for ependymoma, melanoma, carcinomas of lung, bronchus, and trachea, unspecified malignant neoplasms, and non-Hodgkin’s lymphoma. Significant increases were found for gastrointestinal tract cancers and non-Kaposi sarcomas. The age-adjusted mortality rate decreased for acute myeloid leukemia, melanoma, carcinomas of liver and intrahepatic bile ducts, kidney and, in women, leukemia. For some cancers, rates differed by sex, race, ethnicity, and geography. Monitoring the rates and time trends of AYA cancer emphasizes the distinct health concern for this age group.

1. Introduction

Early-onset (<50) cancer incidence rates have increased in the United States and worldwide since the 1990s [1,2,3,4,5]. There are significant concerns that these trends may continue in the future, particularly for Generation X born between 1965–1980 [6,7]. Adolescents and young adults (AYAs) aged 15–39 with cancer are considered a unique population, and different from pediatric or older groups [8]. The recognition of AYA cancer as distinct early-onset cancer is based on the types of tumors and their biology that occur in this age group [8,9]. Additionally, the detection and management of AYA patients entail unique challenges ranging from delays in diagnosis, psychological support, fertility, and financial needs during their transition into older adulthood [8,10,11,12,13,14,15].
Cancer is the leading cause of mortality in AYAs, and comprises about 4.2% of all cancers in the NCI’s Surveillance, Epidemiology, and End Results (SEER) Program [16]. The incidence and types of cancer in AYAs are age-dependent, with Hodgkin’s lymphoma, and central nervous system tumors more common in adolescents, whereas thyroid, testicular and non-Hodgkin’s’ lymphoma are relatively common in the 20–29-year range [16,17]. Young adults aged 30–39 experience cancer types more similar to older young adults (40–49) including GI, melanoma, and breast cancer [16,17].
Their overall incidence and mortality trends from 1973–2015 are shown on SEER’s website [16]. Mortality rates slowly declined since 1992, while incidence rates steadily increased from about 1997 [16]. Monitoring changes in incidence and mortality rates is essential for understanding disease etiology and planning for future needs in the AYA population. During the first year of the COVID-19 epidemic in the USA, there was an increase in underdiagnosed cancer cases in the USA, and COVID-19 may have affected AYAs similarly [18]. The current study was conducted to characterize recent trends of AYA cancer (2016–2021) incidence and mortality rates, and examine these by cancer subtype, sex, race and ethnicity, age group, and metropolitan/nonmetropolitan designation.

2. Materials and Methods

2.1. Data Sources and Acquisition

SEER is a network of population-based cancer registries in geographic areas that represent the racial and ethnic populations in the US [19]. The SEER 22 database used for this analysis encompasses 22 USA regions, representing 47.9% of the US population [20]. The registries routinely collect data on incidence, mortality, primary tumor site, and tumor morphology, year of diagnosis, year of death, age at diagnosis, age at death, sex, race/ethnicity, metropolitan/nonmetropolitan status. SEER-imbedded cancer subtype coding specific for AYA site/histology codes (AYA site recode) was developed to better characterize topography and morphology in AYA and have undergone periodic revision [21]. SEER is the most comprehensive population-based source in the USA that provides de-identified information on cancer patients, which offers opportunity to study cancer epidemiology in AYAs in a convenient fashion without conducting high-cost epidemiological studies that involve blinding or randomization.
For the incidence or mortality analysis, the inclusion criteria included AYAs (age at diagnosis or at death: 15–39 y) with a diagnosis of invasive cancer or who had died from cancer from 1 January 2016 to 31 December 2021. Age, race/ethnicity, sex, and metropolitan/nonmetropolitan designation information were included for both analyses. We excluded all the cancer patients from SEER who were not AYAs (age at diagnosis or age at death <15 y or >39 y), who reported missing information on race/ethnicity, sex, metropolitan/nonmetropolitan designation, age, or the ones whose cancer diagnosis or death occurred before 1 January 2016, or after 31 December 2021.
Both analyses included sociodemographic information of the AYA patients such as age, sex, race/ethnicity, and metropolitan/nonmetropolitan status. Weight information was not included because SEER does not collect weight information of cancer patients. Age ranged from 15–39 years and was categorized into five groups: 15–19, 20–24, 25–29, 30–34, and 35–39. Sex was grouped into female and male. Race/ethnicity group was classified as non-Hispanic White (NHW), non-Hispanic black (NHB), non-Hispanic American Indian/Asian Pacific (NHAIAP), and Hispanic. Metropolitan/nonmetropolitan status was designated based on USDA’s 2013 rural-urban continuum codes (RUCC) at county level imbedded in SEER*Stat [22,23]. Metropolitan counties were distinguished by population size of the metro area (RUCC code 1-3), while nonmetropolitan counties (RUCC code 4-9) by size of the largest city or town and proximity to metro and micropolitan areas (U.S. metropolitan/nonmetropolitan population: 85.9% vs. 14.1%) [24]. In both analyses, the AYAs with missing/unknown metropolitan/nonmetropolitan status from Alaska and/or Hawaii were included as a group of the metropolitan/nonmetropolitan status because this information has been reported in SEER*Stat. However, this group was excluded from the trend analysis stratified by metropolitan/nonmetropolitan designation for its small sample size, which may not generate sufficient statistical power to show significant trend change.
SEER*Stat 8.4.3 was used to calculate age-adjusted incidence and mortality rates and measure annual percentage changes (APC) in age-adjusted cancer incidence and mortality rates as well as significant trends in these rates [25]. Comparison of the rates by race, sex, and metropolitan/nonmetropolitan designation were also calculated using SEER*Stat 8.4.3. Similarly, the age-adjusted incidence rates comparison between two periods: 2020–2021 and 2016–2019 (reference) was done in cancer subtypes. The significance was estimated using the exact mid-p double sided p-value. The current study was exempt from the institutional review board oversight of Penn State for using de-identified and publicly available data from SEER.

2.2. Statistical Analysis

Two SEER methods are used for the calculation of cancer rates and time trends. When an individual case has multiple diagnoses, one method is to calculate the rate based on only the first record for these individuals. The second method counts every cancer diagnosis. We determined that these two methods have a 98% agreement rate. All age-adjusted AYA cancer incidence and mortality rates, reported per 100,000 persons, were calculated using SEER*Stat, version 8.4.3 and age-adjusted to the 2000 US standard population (19 age groups, P25-1130) [26]. Mortality cases were retrieved from cancer registry-determined vital statistics collected as follow-up from the SEER’s incidence-based mortality database [27,28]. Percent changes from 2016 to 2021 in age-adjusted incidence rates and in mortality rates were analyzed by fitting linear regression models with each calendar year at diagnosis or year of death (2016–2021) as an independent variable. Percent changes (significant increasing/decreasing or stable) in age-adjusted incidence and mortality rates from 2016–2021 were assessed using APC calculated based on weighted least square methods and corresponding confidence intervals (CIs) estimated by SEER*Stat 8.4.3. The APC values allow for comparisons between incidence and mortality rate changes in rare and common cancers. Statistically significant APCs were different from zero with two-sided p < 0.05 [25]. Age-adjusted rates, time trends, and rate ratios were determined by cancer subtypes, sex, race/ethnicity, AYA age group, and metropolitan/nonmetropolitan status. For the completeness of data update, crude counts were also provided using SEER*Stat 8.4.3. Because SEER provides all these de-identified data on its website upon request, our findings can be replicated if all the same inclusion and exclusion criteria are adopted. The mortality-to-incidence ratio (MIR), a proxy for AYA cancer survival, was calculated by dividing the age-adjusted mortality rate by the age-adjusted incidence rate, for the selected cancers.

3. Results

3.1. Study Population Characteristics

This study included 229,975 AYAs (aged 15–39 y) diagnosed with invasive cancer (women: 141,091 and men: 88,884) and 29,400 AYAs died from invasive cancer (men: 14,533 and women: 14,867) from 2016 to 2021 (Table 1 and Table S1). The majority of AYAs with cancer diagnosis were NHW (54%), followed by Hispanic (26.1%), NHB (10.6%), and NHAIAP (9.3%) (Table 2). There was a similar racial and ethnic distribution in cancer mortality (Table 2 and Table S1). Most cases occurred in metropolitan areas (metropolitan: 91.3% and nonmetropolitan: 8.6%).

3.2. Age-Adjusted AYA Cancer Incidence Rates and Mortality Rates and MIR

From 2016–2021, the overall age-adjusted incidence rate for AYA was 72.3, and the overall mortality rate was 10.7 (Table 1). Thyroid and gastrointestinal tract carcinomas were the most common incident cases (15.3%) and cancer death (19.2%). Age-adjusted cancer incidence and mortality rates differ in patterns by cancer subtypes. The most common age-adjusted incidence rates were for breast cancer (11.0), thyroid carcinoma (10.9), lymphoma (7.6), carcinoma of gastrointestinal tract (7.5), male testis cancer (5.6), melanoma (5.2), carcinoma of genital sites (5.1), and leukemia (4.6). By contrast, the higher mortality rates were for carcinoma of gastrointestinal tract (2.1), breast cancer (1.2), leukemia (1.1), lymphomas (0.9), astrocytoma (0.9), sarcomas (0.9), and testis cancer (0.4). Melanoma (0.058) and gonadal and related tumors (0.096) had the relatively lower MIR.

3.3. Sociodemographic Differences in AYA Cancer Incidence and Mortality Rates

The age-adjusted incidence rate was significantly higher in females than males (90.9 vs. 54.3, p = 0.027) (Table 2). For males, the common new cases were carcinomas (32.5%). Of these, the most common were testis (21.0%), lymphoma (15.3%), leukemia (9.3%), and melanoma (6.5%) (Table S1). The age-adjusted incidence rate (IR) for testicular cancer was 11.0. For females, carcinoma of breast (23.8%, IR: 22.3), thyroid carcinoma (20.2%), lymphoma (7.9%), melanoma (7.5%), and leukemia (4.7%) were the most common cancers.
The age-adjusted mortality rate was significantly higher in females than males (11.1 vs. 10.3) (Table 2). Stratified by sex, the main causes of death were carcinomas (34.4% and 59.5%), leukemias (13.6% and 8.6%), CNS and other intracranial and intraspinal neoplasms (12% and 7.6%), lymphomas (11% and 5.9%), and sarcomas (10.7% and 7.5%, Table S1). Carcinomas of the breast (2.5) and gastrointestinal tract (2.3) topped mortality rates for female and male AYAs, respectively.
Table 2 also shows the rates by race and ethnicity. The highest age-adjusted incidence rate was among NHW (82.3), and the lowest was among NHAIAP (59.9). While NHAIAP had the lowest overall mortality rate (8.5), NHB had the highest rate (14.4). For females, the age-adjusted incidence rate in NHW was 102.3, which was significantly higher than other races. Similar differences were found for males. NHB had significantly higher mortality rates for both sexes.
Age-adjusted incidence and mortality rates significantly differed by geography (Table 2). The overall age-adjusted incidence and mortality rates were both significantly lower for metropolitan areas (incidence rate: 72.0, mortality rate: 10.5) as compared to nonmetropolitan areas (incidence rate: 76.0 and mortality rate: 12.4). When stratified by sex, the geographic difference in age-adjusted incidence rates was found only in women (Table S1).
Categorized by age group, the findings of the sociodemographic distribution of cancer incidence and mortality rates were mostly consistent, showing higher incidence rates in females vs. males, NHW vs. other racial groups (higher mortality was with NHB), nonmetropolitan vs. metropolitan, with differing patterns in certain age groups (Table 2).

3.4. AYA Age-Adjusted Cancer Incidence Rates and Mortality Trends

Table 3 displays the age-adjusted incidence and mortality trends from 2016–2021 for the major histologic classifications and primary site. There was no significant percent change in the overall age-adjusted cancer incidence rates (APC = −1.2, 95% CI: −3.1, 0.8, p = 0.18) and mortality (APC = −0.5, 95% CI: −1.0, 0.1, p = 0.07) during the study period. The age-adjusted incidence rate increased for non-Kaposi sarcoma (APC = 8.3, p = 0.02), carcinoma of rectum (APC = 2.7, p = 0.01), and gastrointestinal tract (APC = 1.1, p = 0.04). There was a decrease in the incidence of ependymoma (−5.4, p = 0.047), melanoma (−5.1, p = 0.02), carcinoma of lung, bronchus, and trachea (LBT) (−4.5, p = 0.04), unspecified malignant neoplasms (UMN) (−4.3, p = 0.01), liposarcoma (−4.2, p = 0.01), and NHL (−2.6, p = 0.002). A decrease in mortality was found for AML (APC = −3.4, p = 0.047), melanoma (−7.4, p = 0.047), carcinomas of liver and intrahepatic bile duct (IBD) (−4.1, p = 0.02), and kidney (−6, p = 0.02). The death rates increased for UMN (3.5, p = 0.046).

3.5. Sociodemographic Differences in AYA Cancer Incidence and Mortality Trends

When stratified by sex, there were no significant changes in age-adjusted incidence rates for both males (APC = −1.3, p = 0.11) and females (APC = −1.1, p = 0.25) in this period (Table S2). When stratified by type, there was a decreasing trend for melanoma in both men and women (males: −6.4, p = 0.01; females: −4.3, p = 0.032). For males only, age-adjusted cancer incidence rates decreased for NHL (−2.8, p = 0.004) and fibromatous neoplasms (−6.8, p = 0.04), but increased in non-Kaposi sarcoma (9.3, p = 0.04). For females alone, age-adjusted incidence rates increased for ALL (APC = 3.4, p = 0.01) and blood and lymphatic vessel tumors (7.7, p = 0.003), but decreased for ependymoma (−5.9 p = 0.03), lymphoma (−1.6, p = 0.03), GCT (−5.8, p = 0.01), UMN (−6.5, p = 0.009), and synovial sarcoma (−4.4, p = 0.04).
The overall cancer mortality rates significantly decreased for females (APC = −0.8, p = 0.02). In women, a significant reduction was found for leukemia (−2.6, p = 0.03). In men, there was a decline in mortality from leukemias (−1.4, p = 0.01), NHL (−5.9, p = 0.03), and kidney carcinoma (−4.5, p = 0.03). Male mortality increased significantly for other and unspecific leukemia (11.9, p = 0.01) and nerve sheath tumors (15.4, p = 0.047). The rates and trends were more pronounced when calculated using the method that accounts for multiple cancer diagnosis and cancer deaths (Tables S3–S7).
A significant decline of incidence rates in 2020–2021, as compared to 2016–2019, was found in AYAs for NHL (3.38 vs. 3.65), astrocytoma (2.31 vs. 2.43), glioblastoma (0.47 vs. 0.53), melanoma (4.39 vs. 5.3), carcinoma of the thyroid (10.0 vs. 11.07), head and neck (1.34 vs. 1.45), oral cavity, lip, and pharynx (0.65 vs. 0.72), LBT (0.69 vs. 0.83), and genital sites (4.62 vs. 4.98), as well as UMN (0.51 vs. 0.59).
Figure S1 depicts the metropolitan/nonmetropolitan differences in cancer incidence trends. The overall age-adjusted incidence rates were stable for both metropolitan and nonmetropolitan areas (metropolitan: APC = −1.15, p = 0.2; nonmetropolitan: APC = −1.48, p = 0.07). Both metropolitan and nonmetropolitan areas had an increase in non-Kaposi sarcoma (metropolitan: APC = 6.4, p = 0.02; nonmetropolitan: APC = 34.94, p = 0.009). Incidence of rectum carcinoma also increased in metropolitan areas, while ovary carcinoma incidence increased significantly in nonmetropolitan AYAs. Further, NHL (APC = −2.6, p = 0.004), ependymoma (APC = −5.2, p = 0.045), liposarcoma (APC = −4.4, p = 0.01), melanoma (APC = −5.5, p = 0.01), carcinomas of LBT (APC = −4.9, p = 0.04), uterine cervix (APC = −3.3, p = 0.04), and UMN (APC = −4.6, p = 0.01) significantly declined in metropolitan areas. In nonmetropolitan areas, a significant decrease was found for fibromatous neoplasm (APC = −8.5, p = 0.008), thyroid carcinoma (APC = −6.7, p = 0.045), carcinomas of skin (APC = −14.1, p = 0.02), urinary tract (APC = −5, p = 0.03), and kidney (APC = −5.6, p = 0.02).
The mortality rates were stable in both metropolitan and nonmetropolitan areas (metropolitan: APC = −0.35, p = 0.297; nonmetropolitan: APC = −1.78, p = 0.342, Figure S2). In metropolitan areas, mortality rates declined for AML (APC = −3.5, p = 0.01) and carcinoma of kidney (APC = −5.6, p = 0.03), but increased for male testis (APC = 6.2, p = 0.02), carcinoma of esophagus (APC = 9.2, p = 0.02), and gonadal and related tumors (APC = 3.2, p = 0.04). For nonmetropolitan areas, the mortality rate fell for ependymoma (APC = −21.8, p = 0.4), but rose for glioblastoma (APC = 12.1, p = 0.04) and pancreas carcinoma (APC = 14.6, p = 0.047). The mortality of nerve sheath tumors differed between metropolitan and nonmetropolitan areas, with an increase in metropolitan areas (APC = 16.7, p = 0.03), and a fall in nonmetropolitan areas (APC = −23.2, p = 0.009). The results were similar when considering multiple primary cancer diagnoses and deaths (Figures S3 and S4).

4. Discussion

Age-adjusted AYA cancer incidence rates significantly increased by 29.6% from 57.2 to 74.2 between 1973 and 2015 [17]. After rising for over 40 years, the age-adjusted incidence rates of overall cancer were stable as reported in our study between 2016–2021. This may reflect the stable incidence trends of carcinomas of the testis, thyroid, and kidney that were driving the previous rising incidence rates [7,17,29]. The falling incidence trend of melanoma and male NHL reported in our study contradicted the previous finding where the melanoma incidence rates increased drastically, and the trend of male NHL was stable from 1973–2015 [17]. Additionally, we reported a decrease in age-adjusted incidence rates of carcinoma of LBT, while a decline in carcinoma of LBT was only evident in male or female AYAs from the majority of previous data [30,31]. Sex differences in LBT incidence remain to be elucidated [32].
Environmental exposure to poly- and perfluoroalkyl substances, endocrine disruptors, genetic susceptibility, low-birth weight, and suboptimal maternal age may play a role in testis cancer etiology [33,34,35,36]. Thyroid and kidney carcinomas are obesity related [37,38]. Recommendations against screening asymptomatic patients in 2017 could help curb the elevating thyroid incidence rates, stabilizing the incidence rates of thyroid carcinoma in our study [39].
In addition, it may be that changes in modifiable lifestyle risk factors in the population impact these trends. Melanomas tend to affect individuals with light skin and excessive UV exposure [40,41]. The increased use of preventive measures (staying in the shade and wearing long-sleeved clothes) from 2003–2018 in AYAs (59% were NHW) may help shield them from UV exposure, contributing to a decline in melanoma incidence rates [42]. Stratified by sex, a sharp decline in HIV infection rate in young adults (up to 34% reduction during 2017–2021) due to improved prevention, testing, and treatment of HIV might have contributed to a decline in NHL incidence in men [43]. The reported decline in male MHL was also consistent with the findings from the comparison of a incidence trend analysis between Generation X and prior generations [7].
The main effect of COVID-19 in the general population is a decrease in major cancers that can be detected by screening including lung, colon, female breast, and melanoma [44]. This indicates that cancer incidence may be underreported due to pandemics. There was also a decline of melanoma and lung cancer incidence in our study. The decline of other cancer incidence reported in our study likely reflects the impact that COVID-19 had on access to health care and cancer detection.
Age-adjusted incidence rates of all cancers are higher in metropolitan populations, although rates are declining faster in metropolitan than nonmetropolitan areas in the U.S. [45]. Similarly, this study found significantly higher age-adjusted incidence rates of AYA in metropolitan populations. However, no metropolitan/nonmetropolitan difference was reported in AYA cancer incidence time trends. Poor access to health services with imaging utilization and long distances to care facilities could negatively affect nonmetropolitan AYAs’ screening rates, contributing to the decreasing trend of thyroid carcinoma incidence in nonmetropolitan areas [46,47,48].
The mortality rate of 10.7 per 100,000 (with leading causes of death from leukemia, sarcomas, testis tumor, and breast tumor) in the current study for 2016–2021 was higher than for 2012–2016 [49]. The higher rate may be due to an increase in UMN mortality rates since all other types were either stable or falling. This study reported no significant change in the overall mortality rate, which could be attributable to the relatively small contributions (0.2–4% of total mortality counts) of cancer types that showed significant change. Decline in melanoma mortality rate was consistent with the national data (1986–2016), indicating that novel systematic therapies contribute to the decrease [50]. The stable leukemia incidence trend and the declined mortality likely suggest recent treatment advances such as improved treatment regimens from tyrosine kinase inhibitors and allogeneic hematopoietic stem cell transplant [51,52].
This study also found sex differences in overall and site-specific mortality trends. Overall cancer mortality rates significantly decreased 5% in females (largely driven by a decrease in leukemia mortality) whereas the overall mortality rates were stable in male AYAs. While males had significant increase in mortality rates in other and unspecified leukemia and nerve sheath tumors, and decrease in leukemias, NHL, and carcinoma of kidney, the contribution of each of these cancer sites was small (<14%).
Our study has limitations. RUCC (2013) may not fully represent the contemporary picture of geographical regions during 2020–2021 for not capturing the changes made by the U.S. Census Bureau in 2020 to reflect urban area population [23]. However, using SEER provides an excellent opportunity to examine cancer morbidity and mortality in AYAs as a distinctive population.

5. Conclusions

This study provides a recent profile of AYA cancer rates and trends. Unlike the increasing rates in adult-onset cancer, the incidence in AYAs has remained unchanged in recent years. Specific cancers need continued monitoring, and there is a need to identify factors that contribute to the disparities by sex, race/ethnic distribution, and geography.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/cancers16183153/s1, Table S1: AYA cancer incidence and mortality by sex; Figure S1: Incidence trends of subtype cancers by metropolitan/nonmetropolitan status when considering first primary cancer diagnosis (significant change of trends); Table S2: Trends in cancer incidence and mortality for males and females, 2016–2021; Figure S2: Mortality trends of subtype cancers by metropolitan/nonmetropolitan status when considering first primary cancer death (significant change of trends); Table S3: AYA cancer incidence rates (age at diagnosis, 15–39 y), and mortality rates for death from cancer (age at death, 15–39 y) from SEER-22, 2016–2021; Figure S3: Incidence trends of subtype cancers by metropolitan/nonmetropolitan status when considering multiple primary cancer diagnoses (significant change of trends); Table S4: AYA cancer incidence and mortality by sex, 2016–2021; Figure S4: Mortality trends of subtype cancers by metropolitan/nonmetropolitan status when considering multiple primary cancer deaths (significant change of trends); Table S5: AYA cancer demographics by age group, 2016–2021; Table S6: Trends in cancer incidence and mortality, 2016–2021; Table S7: Trends in cancer incidence and mortality for males and females, 2016–2021.

Author Contributions

Conceptualization, L.Z., J.E.M., V.M.C. and C.G.B.; methodology, L.Z., J.E.M., V.M.C. and C.G.B.; software, L.Z.; validation, L.Z., J.E.M. and V.M.C.; formal analysis, L.Z.; investigation, L.Z., J.E.M., V.M.C. and C.G.B.; resources, L.Z. and J.E.M.; data curation, L.Z.; writing—original draft preparation, L.Z.; writing—review and editing, L.Z., J.E.M., V.M.C. and C.G.B.; visualization, L.Z.; supervision, J.E.M. and C.G.B.; project administration, J.E.M. and C.G.B.; funding acquisition, C.G.B. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by Penn State Children’s Hospital Four Diamonds Childhood Cancer Innovation funding. The APC was funded by CGB who received Penn State Children’s Hospital Four Diamonds Childhood Cancer Innovation funding to support this work.

Institutional Review Board Statement

Ethical review and approval were waived for this study due to using de-identified and publicly available data from SEER.

Informed Consent Statement

Informed consent was obtained from all subjects involved in the SEER and in this study.

Data Availability Statement

Data is available on the SEER website, and the analytic methods, and supplemental materials will be made available pending email request to the corresponding author.

Acknowledgments

We thank Penny M. Kris-Etherton from the Department of Nutritional Sciences at Penn State University for her time and efforts in reviewing the manuscript.

Conflicts of Interest

The authors declare no conflicts of interest. This study was supported by Penn State Children’s Hospital Four Diamonds Childhood Cancer Innovation funding. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

References

  1. Koh, B.; Tan, D.J.H.; Ng, C.H.; Fu, C.E.; Lim, W.H.; Zeng, R.W.; Yong, J.N.; Koh, J.H.; Syn, N.; Meng, W.; et al. Patterns in Cancer Incidence Among People Younger Than 50 Years in the US, 2010 to 2019. JAMA Netw. Open 2023, 6, e2328171. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  2. Siegel, R.L.; Giaquinto, A.N.; Jemal, A. Cancer statistics, 2024. CA Cancer J. Clin. 2024, 74, 12–49. [Google Scholar] [CrossRef] [PubMed]
  3. Xu, S.; Murtagh, S.; Han, Y.; Wan, F.; Toriola, A.T. Breast Cancer Incidence Among US Women Aged 20 to 49 Years by Race, Stage, and Hormone Receptor Status. JAMA Netw. Open 2024, 7, e2353331. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  4. Dong, W.; Kim, U.; Rose, J.; Hoehn, R.S.; Kucmanic, M.; Eom, K.; Li, S.; Berger, N.A.; Koroukian, S.M. Geographic Variation and Risk Factor Association of Early Versus Late Onset Colorectal Cancer. Cancers 2023, 15, 1006. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  5. Zhao, J.; Xu, L.; Sun, J.; Song, M.; Wang, L.; Yuan, S.; Zhu, Y.; Wan, Z.; Larsson, S.C.; Tsilidis, K.K.; et al. Global trends in incidence, death, burden and risk factors of early-onset cancer from 1990 to 2019. BMJ Oncol. 2023, 2, e000049. [Google Scholar] [CrossRef]
  6. Ugai, T.; Sasamoto, N.; Lee, H.Y.; Ando, M.; Song, M.; Tamimi, R.M.; Kawachi, I.; Campbell, P.T.; Giovannucci, E.L.; Weiderpass, E.; et al. Is early-onset cancer an emerging global epidemic? Current evidence and future implications. Nat. Rev. Clin. Oncol. 2022, 19, 656–673. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  7. Rosenberg, P.S.; Miranda-Filho, A. Cancer Incidence Trends in Successive Social Generations in the US. JAMA Netw. Open 2024, 7, e2415731. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  8. Turgeman, I.; West, H.J. Adolescents and Young Adults with Cancer. JAMA Oncol. 2023, 9, 440. [Google Scholar] [CrossRef]
  9. Tricoli, J.V.; Blair, D.G.; Anders, C.K.; Bleyer, W.A.; Boardman, L.A.; Khan, J.; Kummar, S.; Hayes-Lattin, B.; Hunger, S.P.; Merchant, M.; et al. Biologic and clinical characteristics of adolescent and young adult cancers: Acute lymphoblastic leukemia, colorectal cancer, breast cancer, melanoma, and sarcoma. Cancer 2016, 122, 1017–1028. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  10. Close, A.G.; Dreyzin, A.; Miller, K.D.; Seynnaeve, B.K.N.; Rapkin, L.B. Adolescent and young adult oncology-past, present, and future. CA Cancer J. Clin. 2019, 69, 485–496. [Google Scholar] [CrossRef] [PubMed]
  11. Janssen, S.H.M.; van der Graaf, W.T.A.; van der Meer, D.J.; Manten-Horst, E.; Husson, O. Adolescent and Young Adult (AYA) Cancer Survivorship Practices: An Overview. Cancers 2021, 13, 4847. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  12. Reuvers, M.J.P.; Gedik, A.; Way, K.M.; Elbersen-van de Stadt, S.M.; van der Graaf, W.T.A.; Husson, O. Caring for Adolescents and Young Adults (AYA) with Cancer: A Scoping Review into Caregiver Burdens and Needs. Cancers 2023, 15, 3263. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  13. Armenian, S.H.; Chao, C. Burden of Morbidity and Mortality in Adolescent and Young Adult Cancer Survivors. J. Clin. Oncol. 2024, 42, 735–742. [Google Scholar] [CrossRef] [PubMed]
  14. Barr, R.D.; Ferrari, A.; Ries, L.; Whelan, J.; Bleyer, W.A. Cancer in Adolescents and Young Adults: A Narrative Review of the Current Status and a View of the Future. JAMA Pediatr. 2016, 170, 495–501. [Google Scholar] [CrossRef] [PubMed]
  15. American Cancer Association. Cancer Facts and Figures 2020; ACS: Washington, DC, USA, 2024. [Google Scholar]
  16. SEER. Cancer Stat Facts: Cancer among Adolescents and Young Adults (AYAs) (Ages 15–39) 2024. Available online: https://seer.cancer.gov/statfacts/html/aya.html (accessed on 21 April 2024).
  17. Scott, A.R.; Stoltzfus, K.C.; Tchelebi, L.T.; Trifiletti, D.M.; Lehrer, E.J.; Rao, P.; Bleyer, A.; Zaorsky, N.G. Trends in Cancer Incidence in US Adolescents and Young Adults, 1973–2015. JAMA Netw. Open 2020, 3, e2027738. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  18. Han, X.; Yang, N.N.; Nogueira, L.; Jiang, C.; Wagle, N.S.; Zhao, J.; Shi, K.S.; Fan, Q.; Schafer, E.; Yabroff, K.R.; et al. Changes in cancer diagnoses and stage distribution during the first year of the COVID-19 pandemic in the USA: A cross-sectional nationwide assessment. Lancet Oncol. 2023, 24, 855–867. [Google Scholar] [CrossRef] [PubMed]
  19. National Cancer Institute. About Surveillance, Epidemiology, and End Results Program (SEER) 2023. Available online: https://seer.cancer.gov/about (accessed on 22 April 2024).
  20. National Cancer Institute. About the SEER Registries 2023. Available online: https://seer.cancer.gov/registries/ (accessed on 19 April 2024).
  21. National Cancer Institute. AYA Site Recode 2020 2021. Available online: https://seer.cancer.gov/ayarecode/aya-2020.html (accessed on 21 April 2024).
  22. National Cancer Institute. Rural Urban Continuum Codes, 2013 2014. Available online: https://seer.cancer.gov/seerstat/variables/countyattribs/ruralurban.html (accessed on 4 April 2024).
  23. Economic Research Service. Rural-Urban Continuum Codes; United States Department of Agriculture: Washington, DC, USA, 2024. Available online: https://www.ers.usda.gov/data-products/rural-urban-continuum-codes/ (accessed on 3 April 2024).
  24. US Department of Agriculture. Rural America at a Glance 2019 Edition; USDA: Washington, DC, USA, 2019. [Google Scholar]
  25. National Cancer Institute. Surveillance Research Program, National Cancer Institute SEER*Stat Software Version 8.4.3. 2024. Available online: https://seer.cancer.gov/seerstat/ (accessed on 18 April 2024).
  26. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat Database: Incidence—SEER Research Limited-Field Data, 22 Registries, Nov 2023 Sub (2000–2021)—Linked to County Attributes—Time Dependent (1990–2022) Income/Rurality, 1969–2022 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Released April 2024, Based on the November 2023 Submission. 2022. Available online: https://seer.cancer.gov/data (accessed on 18 April 2024).
  27. National Cancer Institute. Incidence-Based Mortality 2021. Available online: https://surveillance.cancer.gov/statistics/ibm/ (accessed on 21 December 2023).
  28. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat Database: Incidence-Based Mortality—SEER Research Limited-Field Data, 22 Registries (excl IL and MA), Nov 2023 Sub (2000–2021)—Linked to County Attributes—Time Dependent (1990–2022) Income/Rurality, 1969–2022 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Released April 2024, Based on the November 2023 Submission. 2022. Available online: www.seer.cancer.gov/mortality (accessed on 21 April 2024).
  29. Lim, H.; Devesa, S.S.; Sosa, J.A.; Check, D.; Kitahara, C.M. Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974–2013. JAMA 2017, 317, 1338–1348. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  30. van Der Meer, D.J.; Karim-Kos, H.E.; van Der Mark, M.; Aben, K.K.; Bijlsma, R.M.; Rijneveld, A.W.; van Der Graaf, W.T.; Husson, O. Incidence, Survival, and Mortality Trends of Cancers Diagnosed in Adolescents and Young Adults (15–39 Years): A Population-Based Study in The Netherlands 1990–2016. Cancers 2020, 12, 3421. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  31. Gupta, S.; Harper, A.; Ruan, Y.; Barr, R.; Frazier, A.L.; Ferlay, J.; Steliarova-Foucher, E.; Fidler-Benaoudia, M.M. International Trends in the Incidence of Cancer Among Adolescents and Young Adults. J. Natl. Cancer Inst. 2020, 112, 1105–1117. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  32. Jemal, A.; Miller, K.D.; Ma, J.; Siegel, R.L.; Fedewa, S.A.; Islami, F.; Devesa, S.S.; Thun, M.J. Higher Lung Cancer Incidence in Young Women Than Young Men in the United States. N. Engl. J. Med. 2018, 378, 1999–2009. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  33. Sunderland, E.M.; Hu, X.C.; Dassuncao, C.; Tokranov, A.K.; Wagner, C.C.; Allen, J.G. A review of the pathways of human exposure to poly- and perfluoroalkyl substances (PFASs) and present understanding of health effects. J. Expo. Sci. Environ. Epidemiol. 2019, 29, 131–147. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  34. Faja, F.; Esteves, S.; Pallotti, F.; Cicolani, G.; Di Chiano, S.; Delli Paoli, E.; Lenzi, A.; Lombardo, F.; Paoli, D. Environmental disruptors and testicular cancer. Endocrine 2022, 78, 429–435. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  35. Pluta, J.; Pyle, L.C.; Nead, K.T.; Wilf, R.; Li, M.; Mitra, N.; Weathers, B.; D’Andrea, K.; Almstrup, K.; Anson-Cartwright, L.; et al. Identification of 22 susceptibility loci associated with testicular germ cell tumors. Nat. Commun. 2021, 12, 4487. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  36. McGlynn, K.A.; Cook, M.B. Etiologic factors in testicular germ-cell tumors. Future Oncol. 2009, 5, 1389–1402. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  37. Franchini, F.; Palatucci, G.; Colao, A.; Ungaro, P.; Macchia, P.E.; Nettore, I.C. Obesity and Thyroid Cancer Risk: An Update. Int. J. Environ. Res. Public Health 2022, 19, 1116. [Google Scholar] [CrossRef] [PubMed]
  38. Wilson, K.M.; Cho, E. Obesity and Kidney Cancer. Recent. Results Cancer Res. 2016, 208, 81–93. [Google Scholar] [CrossRef] [PubMed]
  39. Bibbins-Domingo, K.; Grossman, D.C.; Curry, S.J.; Barry, M.J.; Davidson, K.W.; Doubeni, C.A.; Epling, J.W.; Kemper, A.R.; Krist, A.H.; Kurth, A.E.; et al. Screening for Thyroid Cancer: US Preventive Services Task Force Recommendation Statement. JAMA 2017, 317, 1882–1887. [Google Scholar] [CrossRef] [PubMed]
  40. Wang, X.; Langevin, A.M.; Houghton, P.J.; Zheng, S. Genomic disparities between cancers in adolescent and young adults and in older adults. Nat. Commun. 2022, 13, 7223. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  41. Mitra, D.; Luo, X.; Morgan, A.; Wang, J.; Hoang, M.P.; Lo, J.; Guerrero, C.R.; Lennerz, J.K.; Mihm, M.C.; Wargo, J.A.; et al. An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background. Nature 2012, 491, 449–453. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  42. Challapalli, S.D.; Shetty, K.R.; Bui, Q.; Osazuwa-Peters, N.; Adjei Boakye, E. Sun protective behaviors among adolescents and young adults in the United States. J. Natl. Med. Assoc. 2023, 115, 353–361. [Google Scholar] [CrossRef] [PubMed]
  43. Center for Disease Control and Prevention. HIV Declines among Young People and Drives Overall Decrease in New HIV Infections. Available online: https://www.cdc.gov/media/releases/2023/p0523-hiv-declines-among-young-people.html (accessed on 23 May 2023).
  44. London, J.W.; Fazio-Eynullayeva, E.; Palchuk, M.B.; Sankey, P.; McNair, C. Effects of the COVID-19 Pandemic on Cancer-Related Patient Encounters. JCO Clin. Cancer Inform. 2020, 4, 657–665. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  45. Zahnd, W.E.; James, A.S.; Jenkins, W.D.; Izadi, S.R.; Fogleman, A.J.; Steward, D.E.; Colditz, G.A.; Brard, L. Rural–Urban Differences in Cancer Incidence and Trends in the United States. Cancer Epidemiol. Biomark. Prev. 2018, 27, 1265–1274. [Google Scholar] [CrossRef] [PubMed]
  46. McDow, A.D.; Zahnd, W.E.; Angelos, P.; Mellinger, J.D.; Ganai, S. Impact of Rurality on National Trends in Thyroid Cancer Incidence and Long-Term Survival. J. Rural. Health 2020, 36, 326–333. [Google Scholar] [CrossRef] [PubMed]
  47. Regmi, S.; Farazi, P.A.; Lyden, E.; Kotwal, A.; Ganti, A.K.; Goldner, W. Disparities in Thyroid Cancer Diagnosis Based on Residence and Distance from Medical Facility. J. Endocr. Soc. 2024, 8, bvae033. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  48. Charlton, M.; Schlichting, J.; Chioreso, C.; Ward, M.; Vikas, P. Challenges of Rural Cancer Care in the United States. Oncology 2015, 29, 633–640. [Google Scholar] [PubMed]
  49. Lewis, D.R.; Siembida, E.J.; Seibel, N.L.; Smith, A.W.; Mariotto, A.B. Survival outcomes for cancer types with the highest death rates for adolescents and young adults, 1975–2016. Cancer 2021, 127, 4277–4286. [Google Scholar] [CrossRef] [PubMed]
  50. Berk-Krauss, J.; Stein, J.A.; Weber, J.; Polsky, D.; Geller, A.C. New Systematic Therapies and Trends in Cutaneous Melanoma Deaths Among US Whites, 1986–2016. Am. J. Public Health 2020, 110, 731–733. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  51. Bhansali, R.S.; Pratz, K.W.; Lai, C. Recent advances in targeted therapies in acute myeloid leukemia. J. Hematol. Oncol. 2023, 16, 29. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  52. Prescott, K.; Jacobs, M.; Stock, W.; Wynne, J. New Approaches to Treating Challenging Subtypes of ALL in AYA Patients. Curr. Hematol. Malig. Rep. 2020, 15, 424–435. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
Table 1. Age-adjusted AYA cancer incidence rates (age at diagnosis, 15–39 y), and mortality rates for death from cancer (age at death, 15–39 y) from SEER-22, 2016–2021.
Table 1. Age-adjusted AYA cancer incidence rates (age at diagnosis, 15–39 y), and mortality rates for death from cancer (age at death, 15–39 y) from SEER-22, 2016–2021.
Cancer SubtypeIncidenceMortalityMIR
Rate 1Count%Rate 1Count%
1. Hematological malignancies4.614,8616.41.1325311.10.239
1.1 Acute lymphoid leukemia1.13663 0.51300
1.2 Acute myeloid leukemia1.23841 0.41181
2. Lymphomas7.624,82110.80.924738.40.118
2.1 non-Hodgkin lymphoma3.611,684 0.51513
2.2 Hodgkin lymphoma3.311,131 0.2667
3. Brain tumors2.786773.81.028879.80.37
3.1 Astrocytoma (Astroglia and related neoplasms)2.47856 0.92524
4. Sarcomas3.110,0674.40.926709.10.375
4.1 Osteosarcoma0.41187 0.2561
4.2 Chondrosarcoma0.2609 0.071
4.3 Bone tumors0.3839 0.1330
4.4 Soft tissue tumors0.41447 0.2513
4.5 Fibromatous neoplasms0.51758 0.074
4.6 Gastrointestinal stromal tumor0.2575 0.038
5. Blood and lymphatic vessel tumors0.517380.80.25611.90.4
5.1 Specified (non-Kaposi sarcoma)0.1446 0.1142
5.2 Kaposi sarcoma0.41292 0.1419
6. Nerve sheath tumors(malignant)0.14750.20.12130.71.0
7. Gonadal and related tumors7.324,23510.50.719436.60.096
7.1 Testis5.618,668 0.41028
7.2 Ovary1.44322 0.2622
7.3 Germ cell and trophoblastic (GCT)-CNS0.1363 0.070
7.4 GCT (excluding CNS, testis, ovary)0.3874 0.1221
8. Melanoma5.216,4157.10.37492.50.058
9. Carcinomas40.3125,96054.85.113,84747.10.127
9.1 Thyroid carcinoma10.935,174 0.1356
9.2 Carcinoma of head and neck1.54625 0.2653
9.2.1 Nasopharyngeal carcinoma0.2603 0.0108
9.2.2 Lip, oral cavity and pharynx carcinoma0.72284 0.1359
9.2.3 Salivary gland0.41179 0.076
9.3 Carcinoma of gastrointestinal tract7.523,381 2.15636
9.3.1 Carcinoma of esophagus0.1445 0.1212
9.3.2 Carcinoma of stomach0.82386 0.41129
9.3.3 Carcinoma of small intestine0.3794 0.0111
9.3.4 Carcinoma of colon3.310,348 0.61665
9.3.5 Carcinoma of rectum1.64961 0.4965
9.3.6 Carcinoma of anus0.2552 0.0107
9.3.7 Carcinoma of liver and IBD0.41396 0.2669
9.3.8 Carcinoma of gallbladder and other extrahepatic biliary 0.1406 0.1160
9.3.9 Carcinoma of Pancreas0.61943 0.2532
9.4 Carcinoma of lung, bronchus, and trachea0.82578 0.3828
9.5 Carcinoma of skin0.1262 0.018
9.6 Carcinoma of breast11.033,719 1.23234
9.7 Carcinoma of genital sites (non ovary or testis)5.115,946 0.71853
9.7.1 Carcinoma of uterine cervix 3.09373 0.51422
9.8 Carcinoma of urinary tract2.98830 0.3710
9.8.1 Carcinoma of kidney2.37050 0.2543
9.8.2 Carcinoma of bladder0.51691 0.1144
9.9 Carcinoma of other and ill-defined sites, NOS0.51445 0.2559
10. Unspecified Malignant Neoplasms, except CNS0.618490.80.25501.90.333
Any cancer type, Total72.3229,97510010.729,400100
1 All incidence and mortality rates were age-adjusted and reported per 100,000 persons.
Table 2. AYA cancer demographics for 2016–2021 by age group.
Table 2. AYA cancer demographics for 2016–2021 by age group.
Incidence
All15–19 y20–24 y
CharacteristicsRateCount%RateCount%RateCount%
Sex
  Male54.388,88438.623.9780252.335.511,84650.2
  Female90.9 *141,09161.422.7 *710547.737.1 *11,73849.8
Race/ethnicity
  Non-Hispanic White82.3124,16454.025.5738349.541.812,49153.0
  Non-Hispanic Black61.0 *24,37010.616.8 *14229.523.5 *20908.9
  Non-Hispanic American Indian/Asian Pacific59.9 *21,3329.320.7 *11797.931.5 *19348.2
  Hispanic (All Races)65.8 *60,10926.123.6 *492333.135.1 *706929.9
Metropolitan status
  Metropolitan72.0209,90991.323.413,55790.936.421,53791.3
  Nonmetropolitan76.0 *19,8328.622.313359.034.6 *20238.6
  Unknown/missing (Alaska or Hawaii)87.1 *2340.123.0150.139.0240.1
Total72.3229,97510023.314,90710036.323,584100
25–29 y30–34 y35–39 y
RateCount%RateCount%RateCount%
Sex
  Male48.916,96442.666.322,51036.291.029,76233.3
  Female68.7 *22,86357.4121.0 *39,71863.8187.5 *59,66766.7
Race/ethnicity
  Non-Hispanic White67.821,46353.9106.934,17254.9156.248,65554.4
  Non-Hispanic Black43.1 *403610.177.6 *655510.5131.2 *10,26711.5
  Non-Hispanic American Indian/Asian Pacific46.2 *34668.774.7 *59169.5116.4 *88379.9
  Hispanic (All Races)55.8 *10,86227.384.4 *15,58525.1120.6 *21,67024.2
Metropolitan status
   Metropolitan58.436,51291.192.656,94091.5137.581,36391.0
  Nonmetropolitan60.332718.799.5 *52168.4150.1 *79878.9
Unknown/missing (Alaska or Hawaii)70.3440.2125.8 *720.1163.3 *790.1
Total58.639,82710093.262,228100138.689,429100
Mortality
All15–19 y20–24 y
RateCount%RateCount%RateCount%
Sex
  Male10.314,53349.44.0115660.95.6162961.7
  Female11.1 *14,86750.62.7 *74239.13.7 *101038.3
Race/ethnicity
  Non-Hispanic White10.012,62843.03.071637.73.895736.3
  Non-Hispanic Black14.4 *498216.93.8 *27814.75.0 *38714.7
  Non-Hispanic American Indian/Asian pacific8.5 *27299.33.21678.83.72077.8
  Hispanic (All Races)10.8 *906130.83.8 *73738.85.9 *108841.2
Metropolitan status
  Metropolitan10.526,49890.13.4172690.94.7242591.9
  Nonmetropolitan12.4 *28459.73.11678.84.0 *2118.0
  Unknown/missing
  (Alaska or Hawaii)		21.3 *570.27.750.34.930.1
Total10.729,4001003.418981004.62639100
25–29 y30–34 y35–39 y
RateCount%RateCount%RateCount%
Sex
  Male8.1246156.112.0356947.219.9571844.3
  Female6.6 *192843.913.9 *399852.825.8 *718955.7
Race/ethnicity
  Non-Hispanic White6.6177240.312.5336444.522.1581945.1
  Non-Hispanic Black8.6 *70216.017.6 *130717.333.5 *230817.9
  Non-Hispanic American Indian/Asian pacific6.24229.79.7 *6949.118.0 *12399.6
  Hispanic (All Races)8.3 *149334.012.9220229.121.4354127.4
Metropolitan status
  Metropolitan7.2396590.312.7682590.222.311,55789.5
  Nonmetropolitan8.4 *4109.315.5 *7289.627.9 *132910.3
  Unknown/missing (Alaska or Hawaii)22.4 *140.424.5 *140.243.4 *210.3
Total7.4438910012.9756710022.812,907100
* Significant at 0.05 level. All incidence and mortality rates were age-adjusted and reported per 100,000 persons. SEER*Stat reports AYAs with missing/unknown metropolitan/nonmetropolitan status from Alaska or Hawaii.
Table 3. Trends in age-adjusted cancer incidence and mortality rates, 2016–2021.
Table 3. Trends in age-adjusted cancer incidence and mortality rates, 2016–2021.
Cancer SubtypeIncidenceMortality
APC 1 (95% CI)p ValueAPC 1 (95% CI)p Value
1. Leukemias−0.1 (−2.8, 2.6)0.90−1.9 (−2.8, −1.0)0.005
1.1 Acute lymphoid leukemia1.9 (−0.5, 4.3)0.09−1.5 (−4.5, 1.6)0.24
1.2 Acute myeloid leukemia−0.1 (−5.2, 5.2)0.95−3.4 (−6.6, −0.1)0.047
1.3 Chronic myeloid leukemia−1.5 (−3.8, 0.8)0.14−2.8 (−10.9, 6.2)0.43
1.4 Other and unspecified leukemia0.8 (−5.3, 7.2)0.757.5 (−4.2, 20.6)0.16
2. Lymphomas−1.6 (−3.0, −0.3)0.03−1.6 (−5.2, 2.1)0.30
2.1 Non-Hodgkin lymphoma−2.6 (−3.7, −1.5)0.002−3.7 (−8.4, 1.2)0.10
2.2 Hodgkin lymphoma−0.3 (−2.7, 2.1)0.735.0 (−1.6, 12.0)0.11
3. CNS and Other Intracranial and Intraspinal Neoplasms (All behavior)−1.4 (−2.8, 0.1)0.06−0.3 (−4.7, 4.4)0.88
3.1 Astrocytoma (Astroglia and related neoplasms)−1.2 (−3.0, 0.7)0.16−0.1 (−4.4, 4.6)0.97
3.1.1 Oligodendrogliomas0.4 (−4.2, 5.2)0.830.4 (−3.6, 4.6)0.80
3.1.2 Glioblastoma (invasive)−3.0 (−10.7, 5.4)0.37−0.5 (−4.9, 4.1)0.77
3.1.3 Ependymoma (invasive)−5.4 (−10.5, −0.02)0.0471.7 (−10.2, 15.2)0.73
3.1.4 Other astrocytoma/astroglial neoplasms−0.2 (−3.2, 2.8)0.84−0.02 (−6.2, 6.5)0.99
3.2 Medulloblastoma−2.3 (−7.0, 2.7)0.272.2 (−6.3, 11.4)0.52
4. Sarcomas−2.5 (−4.8, −0.3)0.04−0.1 (−2.1, 2.0)0.93
4.1 Osteosarcoma−1.8 (−5.7, 2.1)0.27−1.3 (−8.2, 6.1)0.64
4.2 Chondrosarcoma−1.2 (−8.9, 7.1)0.692.5 (−15.7, 24.5)0.75
4.3 Ewing tumor−2.0 (−6.1, 2.3)0.26−0.6 (−9.0, 8.5)0.85
4.3.1 bone tumors−1.0 (−3.7, 1.7)0.36−3.0 (−9.9, 4.5)0.32
4.3.2 Soft tissue sarcomas−3.5 (−13.8, 8.1)0.444.2 (−9.9, 20.4)0.48
4.4 Fibromatous neoplasms−8.1 (−16.8, 1.5)0.08−7.6 (−19.6, 6.1)0.19
4.5 Liposarcoma−4.2 (−6.7, −1.6)0.01−0.3 (−19.3, 23.2)0.97
4.6 Synovial sarcoma−3.1 (−7.5, 1.6)0.140.8 (−8.3, 10.9)0.82
4.7 Leiomyosarcoma−5.5 (−12.6, 2.1)0.11−9.1 (−18.9, 1.9)0.08
4.8 Rhabdomyosarcoma1.3 (−4.8, 7.8)0.594.7 (−4.4, 14.7)0.23
4.9 Gastrointestinal stromal tumor9.9 (−6.6, 29.2)0.181.9 (−21.0, 31.5)0.84
4.10 Other soft tissue sarcoma−1.7 (−6.3, 3.2)0.393.5 (−3.5, 10.9)0.25
4.11 Other bone tumors−1.9 (−9.4, 6.3)0.5511.4 (−0.7, 24.9)0.06
5. Blood and lymphatic vessel tumors0.4 (−6.4, 7.7)0.87−1.5 (−5.3, 2.6)0.36
5.1.1 Specified (non-Kaposi sarcoma)8.3 (2.6, 14.3)0.0210.9 (−7.4, 32.9)0.19
5.1.2 Kaposi sarcoma−2.1 (−9.6, 6.0)0.50−4.9 (−11.5, 2.2)0.12
6. Nerve sheath tumors(malignant)1.9 (−3.0, 7.0)0.3512.1 (−1.5, 27.6)0.07
7. Gonadal and related tumors−0.5 (−1.5, 0.4)0.192.6 (−0.3, 5.5)0.07
7.1 Testis−0.8 (−2.1, 0.5)0.175.2 (−1.1, 11.9)0.08
7.2 Ovary1.3 (−0.3, 3.0)0.09−0.3 (−7.4, 7.3)0.91
7.3 Germ cell and trophoblastic (GCT)-CNS0.5 (−5.1, 6.5)0.815.6 (−13.7, 29.2)0.49
7.4 GCT (excluding CNS, testis, ovary)−4.6 (−10.1, 1.2)0.09−1.1 (−8.8, 7.2)0.72
8. Melanoma−5.1 (−8.5, −1.6)0.02−7.4 (−14.2, −0.2)0.047
9. Carcinomas−0.7 (−3.0, 1.6)0.43−0.5 (−1.6, 0.7)0.32
9.1 Thyroid carcinoma−2.5 (−6.3, 1.5)0.152.0 (−4.9, 9.5)0.47
9.2 Other carcinoma of head and neck−2.3 (−5.2, 0.7)0.101.2 (−5.2, 7.9)0.64
9.2.1 Nasopharyngeal carcinoma−0.2 (−5.5, 5.5)0.93−0.3 (−17.2, 20.2)0.97
9.2.2 Lip, oral cavity and pharynx−3.0 (−6.0, 0.1)0.061.6 (−8.5, 12.8)0.69
9.2.3 Salivary gland−1.9 (−5.0, 1.4)0.185.6 (−10.2, 24.2)0.40
9.2.4 Other carcinoma of head and neck−2.7 (−11.6, 7.1)0.47−1.2 (−13.0, 12.3)0.81
9.3 Carcinoma of gastrointestinal tract1.1 (0.1, 2.0)0.040.3 (−0.3, 0.9)0.25
9.3.1 Carcinoma of esophagus3.0 (−5.9, 12.9)0.416.7 (−0.2, 14.1)0.05
9.3.2 Carcinoma of stomach−2.0 (−4.4, 0.6)0.10−0.8 (−4.9, 3.4)0.61
9.3.3 Carcinoma of small intestine2.3 (−4.3, 9.3)0.40−3.6 (−14.1, 8.1)0.42
9.3.4 Carcinoma of colon0.9 (−0.7, 2.5)0.201.5 (−3.3, 6.5)0.44
9.3.5 Carcinoma of rectum2.7 (0.9, 4.6)0.010.7 (−2.6, 4.2)0.60
9.3.6 Carcinoma of anus3.0 (−6.2, 13.0)0.433.3 (−10.5, 19.3)0.56
9.3.7 Carcinoma of liver and IBD−1.4 (−6.6, 4.2)0.52−4.1 (−7.0, −1.2)0.02
9.3.8 Carcinoma of gallbladder and other extrahepatic biliary1.1 (−2.3, 4.6)0.42−0.9 (−15.9, 16.8)0.88
9.3.9 Carcinoma of pancreas2.2 (−4.2, 9.1)0.402.6 (−4.5, 10.2)0.38
9.4 Carcinoma of lung, bronchus, and trachea−4.5 (−8.5, −0.3)0.04−2.8 (−7.6, 2.2)0.19
9.5 Carcinoma of skin−5.1 (−13.4, 4.1)0.1919.3 (−15.2, 68.0)0.22
9.6 Carcinoma of breast0.7 (−1.2, 2.6)0.36−1.8 (−5.0, 1.5)0.20
9.7 Carcinoma of genital sites (non ovary or testis)−1.5 (−4.7, 1.8)0.26−0.002 (−5.4, 5.7)0.99
9.7.1 Carcinoma of uterine cervix −3.2 (−6.5, 0.3)0.06−2.3 (−7.5, 3.2)0.30
9.8 Carcinoma of urinary tract−1.3 (−5.2, 2.8)0.43−3.6 (−7.4, 0.5)0.07
9.8.1 Carcinoma of kidney−0.7 (−4.6, 3.4)0.66−6.0 (−10.0, −1.9)0.02
9.8.2 Carcinoma of bladder−3.4 (−9.5, 3.2)0.224.2 (−6.8, 16.5)0.36
9.9 Carcinoma of other and ill-defined sites, NOS4.2 (−0.3, 8.9)0.061.8 (−2.5, 6.4)0.31
10. Miscellaneous specified neoplasms6.5 (−6.4, 21.2)0.252.5 (−3.0, 8.2)0.28
11. Unspecified Malignant Neoplasms, except CNS−4.3 (−7.1, −1.5)0.013.5 (0.1, 7.1)0.046
Any cancer type, Total−1.2 (−3.1, 0.8)0.18−0.48 (−1.0, 0.1)0.07
1 APC: annual percentage change.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Zhang, L.; Muscat, J.E.; Chinchilli, V.M.; Behura, C.G. Trends in Cancer Incidence and Mortality in US Adolescents and Young Adults, 2016–2021. Cancers 2024, 16, 3153. https://doi.org/10.3390/cancers16183153

AMA Style

Zhang L, Muscat JE, Chinchilli VM, Behura CG. Trends in Cancer Incidence and Mortality in US Adolescents and Young Adults, 2016–2021. Cancers. 2024; 16(18):3153. https://doi.org/10.3390/cancers16183153

Chicago/Turabian Style

Zhang, Li, Joshua E. Muscat, Vernon M. Chinchilli, and Chandrika G. Behura. 2024. "Trends in Cancer Incidence and Mortality in US Adolescents and Young Adults, 2016–2021" Cancers 16, no. 18: 3153. https://doi.org/10.3390/cancers16183153

APA Style

Zhang, L., Muscat, J. E., Chinchilli, V. M., & Behura, C. G. (2024). Trends in Cancer Incidence and Mortality in US Adolescents and Young Adults, 2016–2021. Cancers, 16(18), 3153. https://doi.org/10.3390/cancers16183153

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop